JP7814368B2 - 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ - Google Patents

慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ

Info

Publication number
JP7814368B2
JP7814368B2 JP2023501052A JP2023501052A JP7814368B2 JP 7814368 B2 JP7814368 B2 JP 7814368B2 JP 2023501052 A JP2023501052 A JP 2023501052A JP 2023501052 A JP2023501052 A JP 2023501052A JP 7814368 B2 JP7814368 B2 JP 7814368B2
Authority
JP
Japan
Prior art keywords
human patient
patient
ckd
zibotentan
further embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541766A5 (https=
JP2023541766A (ja
Inventor
グレアスリー，ペータル
アールストレーム，クリスティーネ
スクルティック，スタンコ
メンシエス，ロベルト
サンネイカー・ミーケル
メルシエ・アンネ－クリスティーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023541766A publication Critical patent/JP2023541766A/ja
Publication of JP2023541766A5 publication Critical patent/JP2023541766A5/ja
Application granted granted Critical
Publication of JP7814368B2 publication Critical patent/JP7814368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023501052A 2020-07-10 2021-07-09 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ Active JP7814368B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063050147P 2020-07-10 2020-07-10
US63/050,147 2020-07-10
US202163196793P 2021-06-04 2021-06-04
US63/196,793 2021-06-04
PCT/IB2021/056177 WO2022009163A1 (en) 2020-07-10 2021-07-09 Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease

Publications (3)

Publication Number Publication Date
JP2023541766A JP2023541766A (ja) 2023-10-04
JP2023541766A5 JP2023541766A5 (https=) 2024-07-17
JP7814368B2 true JP7814368B2 (ja) 2026-02-16

Family

ID=76959008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501052A Active JP7814368B2 (ja) 2020-07-10 2021-07-09 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ

Country Status (18)

Country Link
US (4) US11730735B2 (https=)
EP (1) EP4178578A1 (https=)
JP (1) JP7814368B2 (https=)
KR (1) KR20230038234A (https=)
CN (2) CN119386017A (https=)
AU (2) AU2021305983B2 (https=)
BR (1) BR112023000406A2 (https=)
CA (1) CA3188345A1 (https=)
CL (1) CL2023000097A1 (https=)
CR (1) CR20230083A (https=)
DO (1) DOP2022000301A (https=)
IL (1) IL299568A (https=)
MX (1) MX2023000276A (https=)
PE (1) PE20230778A1 (https=)
PH (1) PH12023550025A1 (https=)
TW (1) TWI900606B (https=)
UY (1) UY39321A (https=)
WO (1) WO2022009163A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022009163A1 (en) * 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
AU2023321653A1 (en) * 2022-08-12 2025-03-27 Astrazeneca Ab Combination therapies for treatment of cirrhosis with portal hypertension
UY40633A (es) * 2023-02-08 2024-07-31 Astrazeneca Ab Combinación de zibotentán y dapagliflozina para el tratamiento de la enfermedad renal crónica con pr
WO2025133907A1 (en) * 2023-12-18 2025-06-26 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of microvascular angina
WO2025163559A1 (en) 2024-02-01 2025-08-07 Astrazeneca Ab Combination of zibotentan and dapagliflozin for use for the treatment of hypertension
WO2025261457A1 (zh) * 2024-06-21 2025-12-26 深圳信立泰药业股份有限公司 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途
WO2026078068A1 (en) * 2024-10-09 2026-04-16 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106066A1 (en) 2017-11-30 2019-06-06 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US9364458B2 (en) 2013-07-08 2016-06-14 Abbvie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
FI3658140T3 (fi) 2017-02-27 2025-08-12 Idorsia Pharmaceuticals Ltd Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi
US20210338648A1 (en) * 2018-10-01 2021-11-04 Astrazeneca Ab Methods and compositions for reducing serum uric acid
IL297208A (en) 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease
WO2022009163A1 (en) * 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106066A1 (en) 2017-11-30 2019-06-06 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer，2012年，Vol. 118, No. 22，p.5709-5718
Journal of clinical oncology : official journal of the American Society of Clinical Oncology，2013年，Vol. 31, No. 14，p.1740-1747
STERN, Edward et al.，"Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease"，[online], Arthritis Rheumatol，2019年，インターネット＜URL：https://acrabstracts.org/abstract/evaluation-of-the-highly-selective-endothelin-a-receptor-antagonist-zibotentan-in-systemic-sclerosis-associated-chronic-kidney-disease/＞，［2025年7月10日検索］
The Journal of pharmacology and experimental therapeutics，2017年，Vol. 361, No. 2，p.322-333

Also Published As

Publication number Publication date
PH12023550025A1 (en) 2024-03-11
CN115803028A (zh) 2023-03-14
CA3188345A1 (en) 2022-01-13
BR112023000406A2 (pt) 2023-01-31
TWI900606B (zh) 2025-10-11
AU2024204913A1 (en) 2024-08-01
EP4178578A1 (en) 2023-05-17
US20240358698A1 (en) 2024-10-31
IL299568A (en) 2023-02-01
JP2023541766A (ja) 2023-10-04
US20260027112A1 (en) 2026-01-29
CN119386017A (zh) 2025-02-07
US11730735B2 (en) 2023-08-22
US20230364077A1 (en) 2023-11-16
TW202216147A (zh) 2022-05-01
AU2021305983A1 (en) 2023-03-02
WO2022009163A1 (en) 2022-01-13
AU2021305983B2 (en) 2024-05-16
CL2023000097A1 (es) 2023-09-01
CR20230083A (es) 2023-05-16
PE20230778A1 (es) 2023-05-09
US20220023295A1 (en) 2022-01-27
UY39321A (es) 2022-01-31
US12409174B2 (en) 2025-09-09
DOP2022000301A (es) 2023-01-31
KR20230038234A (ko) 2023-03-17
US12121517B2 (en) 2024-10-22
MX2023000276A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
JP7814368B2 (ja) 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
Khder et al. Sacubitril/valsartan (LCZ696) in heart failure
JP6151123B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP2017145251A (ja) 糖尿病の合併症のための療法
EP3801542B1 (en) Methods of treating subjects having diabetes with chronic kidney disease
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
JP2022548725A (ja) 腎臓病の治療におけるｐｐａｒデルタアゴニストの使用
JP2022526914A5 (https=)
HK40090059A (zh) 用於治疗慢性肾病的齐泊腾坦和达格列净的组合
EA050364B1 (ru) Комбинация зиботентана и дапаглифлозина для лечения хронического заболевания почек
US10624883B2 (en) Pulmonary hypertension preventative or therapeutic agent containing component exhibiting selenoprotein P activity-inhibiting effect
EA052076B1 (ru) Комбинация зиботентана и дапаглифлозина для лечения хронического заболевания почек
US10292949B2 (en) Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction
JP2007509900A (ja) Ａｔ１−アンタゴニスト、アミロライドまたはトリアメテリンおよび利尿剤の組み合わせ
HK40038946B (zh) 治疗患有慢性肾脏疾病的糖尿病受试者的方法
EA044411B1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260203

R150 Certificate of patent or registration of utility model

Ref document number: 7814368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150